Table 3

 Representative studies of the effect of a combination of long acting bronchodilators and inhaled steroids in COPD

StudyNo of patientsDuration(years)Mean FEV1(% predicted)ComparisonOutcome
TRISTAN31719144%Salmererol 50 μg/fluticasone 500 μg twice daily25% reduction in rate of exacerbations. 39% reduction in rate of exacerbations requiring steroids
Hanania903630.542%Salmererol 50 μg/fluticasone 500 μg twice dailyNo difference in number of exacerbations and time to first exacerbation
Calverley27510136%Formoterol 24 μg/budesonide 400 μg twice dailyProlonged time to first moderate exacerbation; risk reduction 42%. Reduced exacerbation rate by 24%
Szafranski26413136%Formoterol 24 μg/budesonide 400 μg twice dailyReduced exacerbation rate from 1.87 to 1.42 per patient year